LBX(SH:603883)2021-10-29 16:00Financial Performance - The company's operating revenue for Q3 2021 was CNY 3,819,669,547, representing an increase of 11.26% compared to the same period last year[4]. - The net profit attributable to shareholders for Q3 2021 was CNY 126,765,938, a decrease of 16.23% year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 113,991,205, down 19.72% from the previous year[4]. - The basic earnings per share for Q3 2021 was CNY 0.31, a decrease of 10.49% compared to the same period last year[5]. - The company reported a total of CNY 11,280,378,196 in operating revenue for the year-to-date, reflecting an increase of 11.47% year-on-year[6]. - The net profit attributable to shareholders for the year-to-date was CNY 532,624,839, an increase of 12.03% compared to the same period last year[6]. - The company achieved a total operating revenue of CNY 1,128,037.82 million for the first three quarters of 2021, representing a year-on-year growth of 11.47%[16]. - The net profit attributable to shareholders for the same period was CNY 53,262.48 million, with a year-on-year increase of 9.29%, and a 12.03% increase when adjusted for new leasing standards[16]. Cash Flow and Assets - The net cash flow from operating activities for the period was CNY 607,958,986, an increase of 4.14% year-on-year[5]. - Total assets at the end of the reporting period were CNY 14,813,280,988, an increase of 31.28% compared to the end of the previous year[5]. - Cash flow from operating activities for the first three quarters of 2021 was CNY 12,793,290,951, an increase from CNY 11,485,363,510 in the same period of 2020[37]. - The total assets as of the third quarter of 2021 were CNY 14,813,280,988, compared to CNY 11,284,109,040 in the previous year, reflecting a growth of 31.56%[33]. - The total liabilities as of the third quarter of 2021 amounted to CNY 10,031,652,210, significantly higher than CNY 6,478,731,148 in the previous year[34]. - The total equity attributable to shareholders reached CNY 4,379,497,882, compared to CNY 4,289,907,961 in the same period last year, showing a growth of 2.09%[34]. Business Operations and Strategy - The company is closely monitoring the pandemic situation and adjusting its operational strategies to minimize impacts on business performance[17]. - The company opened many new stores, which contributed to short-term losses during the cultivation period, impacting overall profitability[17]. - The company has expanded its marketing network to cover 22 provincial markets and over 140 cities, employing a multi-faceted approach to penetrate lower-tier markets[26]. - The company completed two acquisition projects during the reporting period, including a cash payment of 209.53 million yuan for a 35% stake in Zhenjiang Huakang Pharmacy and a 49% stake in Jiangsu Baijiahui Pharmacy, with ongoing acquisition of 51% stake in Hebei Huatuo Pharmacy for 1.428 billion yuan[24]. - The company has established a digital transformation blueprint, focusing on enhancing data supply chains and digital organizational structures, with significant progress in various business domains[26]. Retail and Market Performance - Retail business revenue from October 1 to October 28, 2021, showed a year-on-year growth rate higher than the overall retail revenue growth for the first three quarters[17]. - The gross margin for the retail segment was 36.63%, with a year-on-year increase of 0.78 percentage points[18]. - The revenue from the Chinese patent medicine segment was CNY 9,050,204,922, with a year-on-year growth of 17.06%[19]. - The company reported a gross margin of 51.12% for traditional Chinese medicine, reflecting a 0.76 percentage point increase year-on-year[19]. - The North China region saw the highest revenue growth at 34.13%, contributing significantly to the overall revenue increase[20]. Store and Product Development - As of September 30, 2021, the company operated a total of 8,163 stores, including 6,055 direct-operated stores and 2,108 franchised stores, with 1,866 new stores added during the reporting period[21]. - The company reported a total of 600 self-owned brand products, with sales reaching 1.37 billion RMB in the first three quarters of 2021, a year-on-year increase of 75%[27]. - The company's self-owned brand sales accounted for over 16.8% of total sales in the third quarter, an increase of 8 percentage points year-on-year[27]. - The company’s flagship stores generated an average daily sales of 779,000 yuan, with a daily efficiency of 201 yuan per square meter[23]. - The average daily sales for small and medium-sized stores reached 2.466 million yuan, with an average daily efficiency of 45 yuan per square meter[23]. Financial Management and Investments - The company plans to raise up to CNY 1,740.45 million through a non-public offering to fund new chain pharmacy projects and digital platform development[15]. - The company’s long-term borrowings increased to CNY 985,828,455 from CNY 118,000,000, indicating a significant rise in financing activities[34]. - The company reported a decrease in credit impairment losses to CNY -1,544,646 from CNY -3,625,116 year-over-year[35]. - The company paid out ¥296,350,468 in dividends, compared to ¥164,033,782 in the previous year, representing an increase of 80.5%[39].